Business Context and Reporting Period
This Form 8-K is filed by Novus Therapeutics, Inc. (NVUS), a Delaware corporation, on April 21, 2020. The report addresses a notice from the Nasdaq Stock Market LLC regarding the Company's compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory listing status rather than financial performance.
Material Changes
The primary material change is an extension of the compliance period for the Nasdaq Minimum Bid Price Requirement. Previously, the Company had until August 3, 2020, to regain compliance. Due to current market conditions, Nasdaq issued a "Tolling Notice" extending the deadline to October 19, 2020. The Company remains listed on The Nasdaq Capital Market during this period.
Outlook, Risks, and Management Commentary
Management notes that the Tolling Notice does not impact the Company's current listing status. To regain compliance, the closing bid price of the Company's common stock must reach at least $1.00 per share for a minimum of 10 consecutive business days prior to the new deadline of October 19, 2020. The risk of delisting remains if this price threshold is not met by the extended date.
Investor Verification Checklist
- Verify the current trading price of NVUS common stock relative to the $1.00 minimum bid price requirement.
- Confirm the new compliance deadline of October 19, 2020, for regaining Nasdaq listing standards.
- Monitor future 8-K filings for any further notices regarding delisting or additional extensions.
- Note that the registrant name in the filing header is Novus Therapeutics, Inc., despite the metadata reference to Eledon Pharmaceuticals, Inc.